| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1016933503 |
| P356 | DOI | 10.1007/S10637-014-0163-9 |
| P698 | PubMed publication ID | 25342139 |
| P2093 | author name string | Keunchil Park | |
| Myung-Ju Ahn | |||
| Jin Seok Ahn | |||
| Jong-Mu Sun | |||
| Eun Hye Jho | |||
| Bo Mi Ku | |||
| Yeon-Hee Bae | |||
| P2860 | cites work | 14-3-3 Inhibits Bad-Induced Cell Death through Interaction with Serine-136 | Q24291932 |
| Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models | Q24306326 | ||
| PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer | Q24338724 | ||
| The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis | Q24650902 | ||
| Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation | Q27684731 | ||
| MEK1 mutations confer resistance to MEK and B-RAF inhibition | Q27777362 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers | Q27851426 | ||
| In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer | Q45842339 | ||
| A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens | Q82758717 | ||
| Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 | ||
| Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study | Q27851971 | ||
| Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials | Q27852946 | ||
| Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. | Q27852991 | ||
| 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation | Q28144100 | ||
| Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase | Q28145921 | ||
| KRAS mutations in non-small cell lung cancer | Q28240568 | ||
| RAS oncogenes: weaving a tumorigenic web | Q28250360 | ||
| Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) | Q28297419 | ||
| Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo | Q28476362 | ||
| Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim | Q28749134 | ||
| Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy | Q33316645 | ||
| High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886) | Q33717222 | ||
| RAS Interaction with PI3K: More Than Just Another Effector Pathway | Q34202692 | ||
| Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells | Q34273541 | ||
| Ras family signaling: therapeutic targeting | Q35087208 | ||
| The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells | Q35469548 | ||
| Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells | Q35667143 | ||
| 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors | Q35778060 | ||
| STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17 | Q36083385 | ||
| Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic | Q36945203 | ||
| (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway | Q37112466 | ||
| Genetic predictors of MEK dependence in non-small cell lung cancer | Q37113682 | ||
| Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. | Q37396608 | ||
| Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor | Q37517706 | ||
| Ras signaling and therapies | Q37548931 | ||
| Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy? | Q37797818 | ||
| KRAS Mutations in Lung Cancer | Q38057476 | ||
| Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. | Q38140353 | ||
| KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies | Q39213209 | ||
| Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib | Q39271324 | ||
| KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach | Q39720116 | ||
| Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines | Q39819940 | ||
| PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers | Q39859169 | ||
| AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
| Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor | Q40164535 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | selumetinib | Q7448840 |
| P304 | page(s) | 12-21 | |
| P577 | publication date | 2014-10-25 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer | |
| P478 | volume | 33 |
| Q37421296 | Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037. |
| Q37214847 | Enhancement of hyperthermia-induced apoptosis by 5Z-7-oxozeaenol, a TAK1 inhibitor, in A549 cells |
| Q38731776 | K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target? |
| Q91826369 | Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy |
| Q38836927 | Selumetinib in the treatment of non-small-cell lung cancer |
| Q36398758 | Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities. |
| Q38740315 | Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations |
| Q92135408 | The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer |
| Q38860372 | The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines |
Search more.